NEW YORK, May 16, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Incyte Corporation (NASDAQ: INCY), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Medivation Inc. (NASDAQ: MDVN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2548-100free.
--
Celgene Corporation Analyst Notes
Celgene Corporation (Celgene) posted on their events page that the Company will participate in the following upcoming conferences: The American Society of Clinical Oncology Annual Meeting - May 30 to June 3, 2014 at the McCormick Place, 2301 S Lake Shore Dr., Chicago, Illinois; and at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting - May 31 to June 4, 2014 at the Palais des Congrès de Montréal, 1001 Place Jean-Paul-Riopelle, Montréal, QC H2Z 1H2, Canada. The full analyst notes on Celgene are available to download free of charge at:
http://www.analystsreview.com/2548-CELG-16May2014.pdf
--
Biogen Idec Inc. Analyst Notes
On May 12, 2014, Biogen Idec Inc. (Biogen Idec) and Swedish Orphan Biovitrum AB (Sobi) announced their plans to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia (WFH) 2014 World Congress. The Company noted that Hemophilia is a rare, chronic, inherited disorder in which the ability of a person's blood to clot is impaired. According to the Company, the donation is expected to enable a predictable, sustained humanitarian supply of factor therapy and improve the quality of patient care and outcomes in the developing world. "All of us at Biogen Idec are dedicated to making life better for people living with hemophilia," said George A. Scangos, Ph.D., CEO of Biogen Idec. "Hemophilia occurs all over the world, and this donation will provide some level of care to thousands of people who otherwise would not have access to treatment." The full analyst notes on Biogen Idec are available to download free of charge at:
http://www.analystsreview.com/2548-BIIB-16May2014.pdf
--
Incyte Corporation Analyst Notes
On May 13, 2014, stocks of Incyte Corporation (Incyte) fell 0.42% to end trading at $54.16per share. Over the past five trading sessions, Incyte's stocks gained 1.46% over the Nasdaq Composite which increased 0.15% during the same period. The full analyst notes on Incyte are available to download free of charge at:
http://www.analystsreview.com/2548-INCY-16May2014.pdf
--
Jazz Pharmaceuticals plc Analyst Notes
On May 13, 2014, Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) announced that Matt Young, Senior Vice President and CFO, will provide an overview of the Company and a business and financial update in the following conferences: UBS Global Healthcare Conference in New York, New York on Tuesday, May 20, 2014 at 8:00 a.m. EDT/1:00 p.m. Indian Standard Time(IST); and Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 10, 2014 at 8:00 a.m. PDT/4:00 p.m. IST. Jazz Pharmaceuticals informed that the live webcast of the presentations and an archive of the same for at least one week will be available through the Company's website. The full analyst notes on Jazz Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/2548-JAZZ-16May2014.pdf
--
Medivation Inc. Analyst Notes
On May 12, 2014, Medivation Inc. (Medivation) reported that it will participate in the following conferences: UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 12:00 p.m. ET at the Sheraton New York Times Square Hotel, New York, New York; and the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 8:00 a.m. ET at the Grand Hyatt, New York, New York. The Company informed that the live audio webcast for both conferences may be accessed by visiting the investors section of Medivation's website. Additionally a replay of the webcast will be available on the Company's website for 30 days following the live event. The full analyst notes on Medivation are available to download free of charge at:
http://www.analystsreview.com/2548-MDVN-16May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
